6533b837fe1ef96bd12a1d46

RESEARCH PRODUCT

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

Giulio Andrea ZanazzoAngela TamburiniElisabetta ViscardiPaolo D'angeloRoberto LukschCarla ManzittiRiccardo HauptClaudio FavreMaurizio BianchiAlberto GaraventaBruno De BernardiFiorina CasaleMassimo ConteStefano ParodiDaniela Dau

subject

OncologyMaleCancer Researchmedicine.medical_specialtyPediatricsRisk factors MYCNNeuroblastomaSurvival relapse progressionRisk FactorsNeuroblastomaInternal medicinemedicineHumansStage (cooking)Risk factorChildSurvival analysisRetrospective StudiesSalvage Therapybusiness.industryCancerInfantRetrospective cohort studymedicine.diseaseSurvival AnalysisConfidence intervalOncologyItalyChild PreschoolCohortDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessChildhood cancer

description

The Italian Neuroblastoma Registry was investigated to describe 781 children with neuroblastoma experiencing tumour recurrence (424 progressions and 357 relapses). Ten-year overall survival (OS) was 6.8% (95% confidence interval (CI) 4.3-10.0) after progression and 14.4% (95% CI 10.5-18.9) after relapse. For both circumstances, OS was better for age at diagnosis <18 months, less advanced International Neuroblastoma Staging System (INSS) stage, normal lactate dehydrogenase (LDH) serum level, normal MYCN gene status (P<0.001) and a non-abdominal primary site (P=0.034 for progression, and P=0.004 for relapses). A local type of recurrence had a significantly better outcome only in case of relapse (P<0.001). Probability of survival increased by era of diagnosis. Survival of children with recurrent neuroblastoma is very poor. A small cohort of patients, mainly represented by children with stages 1 and 2 who underwent local recurrence or developed late relapse may still benefit from further conventional treatment. For the remaining larger proportion of patients, experimental therapies should be proposed.

yearjournalcountryeditionlanguage
2009-11-01European journal of cancer (Oxford, England : 1990)
10.1016/j.ejca.2009.06.010https://pubmed.ncbi.nlm.nih.gov/19616426